Page last updated: 2024-08-16

triazolam and itraconazole

triazolam has been researched along with itraconazole in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (33.33)	18.2507
2000's	6 (40.00)	29.6817
2010's	4 (26.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Neuvonen, PJ; Olkkola, KT; Varhe, A	2
Kahn, G	1
Kitada, M; Kiuchi, M; Nakamura, H; Nakasa, H; Ohmori, S; Ono, S; Tsutsui, M	1
Balian, JD; Flockhart, DA; Yuan, R	1
Al-Dirbashi, OY; Kaddoumi, A; Nakashima, K; Nakashima, MN; Yamamoto, K	1
Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M	1

Reviews

2 review(s) available for triazolam and itraconazole

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. Journal of clinical pharmacology, 1999, Volume: 39, Issue:11 Topics: Alprazolam; Anti-Anxiety Agents; Data Collection; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Humans; Itraconazole; Ketoconazole; Midazolam; Triazolam	1999

Trials

2 trial(s) available for triazolam and itraconazole

Article	Year
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 1 Topics: Administration, Oral; Adult; Analysis of Variance; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Synergism; Female; Half-Life; Humans; Itraconazole; Ketoconazole; Male; Reference Values; Triazolam	1994
The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clinical pharmacology and therapeutics, 1996, Volume: 60, Issue:3 Topics: Adult; Analysis of Variance; Antifungal Agents; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Half-Life; Humans; Hypnotics and Sedatives; Itraconazole; Male; Time Factors; Triazolam	1996

Article

Year

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.

Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 1

Topics: Administration, Oral; Adult; Analysis of Variance; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Synergism; Female; Half-Life; Humans; Itraconazole; Ketoconazole; Male; Reference Values; Triazolam

1994

The effect of ingestion time interval on the interaction between itraconazole and triazolam.

Clinical pharmacology and therapeutics, 1996, Volume: 60, Issue:3

Topics: Adult; Analysis of Variance; Antifungal Agents; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Half-Life; Humans; Hypnotics and Sedatives; Itraconazole; Male; Time Factors; Triazolam

1996

Other Studies

11 other study(ies) available for triazolam and itraconazole

Article	Year
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5 Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution	2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Systemic antifungal drugs and drug interactions. Journal of the American Academy of Dermatology, 1996, Volume: 35, Issue:1 Topics: Administration, Oral; Antifungal Agents; Drug Interactions; Humans; Hypnotics and Sedatives; Itraconazole; Triazolam	1996
Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. European journal of clinical pharmacology, 1998, Volume: 54, Issue:2 Topics: Anticonvulsants; Cyclosporine; Cytochrome P-450 Enzyme System; Dihydroergotamine; Drug Interactions; Humans; In Vitro Techniques; Isoxazoles; Itraconazole; Ketoconazole; Metabolic Clearance Rate; Miconazole; Triazolam; Zonisamide	1998
Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. Journal of pharmaceutical and biomedical analysis, 2003, Jan-15, Volume: 30, Issue:6 Topics: Animals; Chromatography, High Pressure Liquid; Drug Interactions; Itraconazole; Male; Microdialysis; Rats; Rats, Wistar; Triazolam	2003
Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:6 Topics: Administration, Oral; Anti-Anxiety Agents; Antifungal Agents; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Humans; Itraconazole; Models, Biological; Time Factors; Triazolam	2010